J&J Builds Oncology Presence: Zarnestra, Yondelis Slated For Filing In 2005
Executive Summary
Johnson & Johnson expects to file NDAs for two oncologics - Zarnestra and Yondelis - as early as the first half of 2005, Pharmaceutical R&D President Harlan Weisman, MD, told analysts July 13